💰 10-Year Market Opportunity (2025-2035)
- PrEP Market: $8.2B → $24.7B (3x growth)
- Treatment Market: $32.1B → $41.8B (30% growth)
- Combined TAM: $66.5B opportunity by 2035
- Gilead Share Potential: 45-65% across segments
📈 Patient Opportunity Analysis
- Base Scenario: 2.8M PrEP + 1.1M TX patients
- Optimistic Scenario: 4.2M PrEP + 1.3M TX patients
- Delta: +1.4M incremental patient opportunity
- PrEP:TX Ratio Evolution: 1.5:1 → 3.2:1 by 2035
📊 PrEP Adoption Evolution & Patient Ratios
PrEP Adoption Timeline
2025: 18%2030: 45%2035: 72%
PrEP:TX Patient Ratio
2025: 1.5:12030: 2.3:12035: 3.2:1
$66.5B
Total TAM by 2035
+1.4M
Incremental Patients (Δ)
3.2:1
PrEP:TX Ratio 2035
72%
Peak PrEP Adoption
⚠️ Key Risks
Slower PrEP adoption rates than forecasted
Competitive long-acting therapies from rivals
Regulatory delays in Ex-US markets
Healthcare infrastructure limitations
Pricing pressure from health systems
🚀 Key Opportunities
First-mover advantage in LAI PrEP
Public-private partnerships for access
Digital health integration opportunities
Combination prevention strategies
Emerging market expansion potential
🌪️ Tornado Analysis - Revenue Impact Sensitivity
PrEP Adoption Rate
-$8.2B
+$12.1B
LAI Launch Success
Competitive Entry
Monte Carlo Results (10,000 runs)
P90: $18.2B revenue scenario
P50: $24.7B revenue scenario
P10: $31.8B revenue scenario
95% confidence interval: $16.8B - $33.2B
🎯 Strategic Recommendations
1. Accelerate LAI Portfolio: Fast-track cabotegravir competitor with $500M investment
2. PrEP Market Expansion: Target 2.5M patients by 2030 through provider partnerships
3. Global Market Access: Secure reimbursement in 15+ countries by 2027
4. Real-World Evidence: Build outcomes database across 50K+ patients
5. Digital Integration: Launch adherence platform for PrEP patients
6. Risk Mitigation: Establish contingency plans for competitive scenarios
Bottom Line: Execute aggressive PrEP expansion while defending Treatment franchise - potential to capture $30B+ of $66B TAM by 2035